{"url":"https://lda.gov/api/v1/filings/e6e924c4-14f5-4ad1-a066-710fceaf4bb2/","filing_uuid":"e6e924c4-14f5-4ad1-a066-710fceaf4bb2","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/e6e924c4-14f5-4ad1-a066-710fceaf4bb2/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Carl Kime","dt_posted":"2025-04-16T16:25:26-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"511 C Street NE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":10800,"url":"https://lda.gov/api/v1/registrants/10800/","house_registrant_id":31822,"name":"INNOVATIVE FEDERAL STRATEGIES, LLC","description":"government relations","address_1":"511 C Street NE","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM TATUM","contact_telephone":"+1 202-347-5990","dt_updated":"2026-02-25T15:09:04.247786-05:00"},"client":{"id":63561,"url":"https://lda.gov/api/v1/clients/63561/","client_id":63561,"name":"ACURX PHARMACEUTICALS, INC.","general_description":"biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-11-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R.____/S.____, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.____/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63116,"prefix":null,"prefix_display":null,"first_name":"CARL","nickname":null,"middle_name":null,"last_name":"KIME","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":12806,"prefix":null,"prefix_display":null,"first_name":"LETITIA","nickname":null,"middle_name":null,"last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":79144,"prefix":null,"prefix_display":null,"first_name":"ERYNN","nickname":null,"middle_name":"D","last_name":"HOOK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}